Spots Global Cancer Trial Database for unresectable melanoma

Every month we try and update this database with for unresectable melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma	NCT03153085	Melanoma Stage ... Melanoma Stage ...	TBI-1401(HF10) Ipilimumab	20 Years -	Takara Bio Inc.
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma	NCT04598009	Melanoma Stage ... Melanoma Stage ...	Binimetinib Imatinib	18 Years -	University of California, San Francisco
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI	NCT01266603	Melanoma	HDIL-2 recMAGE-A3 + AS...	18 Years -	M.D. Anderson Cancer Center
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma	NCT03033576	Clinical Stage ... Clinical Stage ... Melanoma of Unk... Mucosal Melanom... Unresectable Cu... Unresectable Me...	Ipilimumab Nivolumab	18 Years -	National Cancer Institute (NCI)
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	NCT01902173	Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib	18 Years -	National Cancer Institute (NCI)
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	NCT02910700	Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib	18 Years -	M.D. Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma	NCT03865212	Clinical Stage ... Clinical Stage ... Metastatic Chor... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Me...	Recombinant Ves...	18 Years -	Mayo Clinic
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer	NCT05361174	Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm...	IOV-4001	18 Years -	Iovance Biotherapeutics, Inc.
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma	NCT02302339	Melanoma	glembatumumab v... glembatumumab v... glembatumumab v... glembatumumab v...	18 Years -	Celldex Therapeutics
Post-ATU Study of Nivolumab	NCT03325257	Melanoma	Routine care	18 Years -	Nantes University Hospital
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	NCT01989585	Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma	NCT06151847	Clinical Stage ... Metastatic Mela... Pathologic Stag... Unresectable Me...	Biospecimen Col... Cyclophosphamid... Echocardiograph... Fludarabine Interleukin-2 Lifileucel Magnetic Resona... Multigated Acqu... Tumor Resection	18 Years - 70 Years	University of Kansas Medical Center
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma	NCT04688658	Unresectable Me...	Nivolumab Duvelisib	18 Years -	University of Pittsburgh
Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma	NCT05398640	Unresectable Me... Metastatic Mela...	Lifileucel	18 Years -	Iovance Biotherapeutics, Inc.
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	NCT04521075	Melanoma Stage ... Unresectable Me... NSCLC Stage IV	Fecal Microbial...	18 Years -	Ella Therapeutics Ltd
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	NCT04527549	Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me...	Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime...	18 Years -	Eastern Cooperative Oncology Group
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)	NCT03679767	Metastatic Non-... Locally Advance... Metastatic Urot... Unresectable Me... Metastatic Mela... Locally Advance... Metastatic Clea...	Retifanlimab	18 Years -	Incyte Corporation
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	NCT02965716	Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Pembrolizumab Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery	NCT02158520	Metastatic Mela... Mucosal Melanom... Stage IV Cutane... Stage IV Uveal ... Unresectable Me...	Bevacizumab Ipilimumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Academic and Community Cancer Research United
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma	NCT04688658	Unresectable Me...	Nivolumab Duvelisib	18 Years -	University of Pittsburgh
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung	NCT05717140	Clinical Stage ... Metastatic Mali... Metastatic Mela... Recurrent Melan... Unresectable Me...	Aerosol Sargram... Biospecimen Col... Computed Tomogr... Magnetic Resona... Medical Device ... Nivolumab	18 Years -	Mayo Clinic
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma	NCT04759846	BRAF V600 Mutat... Unresectable Me... Metastatic Mela... Hepatic Impairm...	Encorafenib + B... Encorafenib + B... Encorafenib + B...	18 Years -	Pierre Fabre Medicament
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	NCT04521075	Melanoma Stage ... Unresectable Me... NSCLC Stage IV	Fecal Microbial...	18 Years -	Ella Therapeutics Ltd
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung	NCT05717140	Clinical Stage ... Metastatic Mali... Metastatic Mela... Recurrent Melan... Unresectable Me...	Aerosol Sargram... Biospecimen Col... Computed Tomogr... Magnetic Resona... Medical Device ... Nivolumab	18 Years -	Mayo Clinic
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma	NCT04493203	Advanced Melano... Unresectable Me...	Nivolumab Axitinib	18 Years -	University of Pittsburgh
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT03021460	Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Sargramostim (GM-CSF) + PD-1	NCT04703426	Unresectable Me... Metastatic Mela... Stage III Melan... Stage IV Melano...	Sargramostim (G... Pembrolizumab (...	18 Years -	Dana-Farber Cancer Institute
NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma	NCT04625205	Unresectable Me... Metastatic Mela...	NEO-PTC-01 IL-2 αPD-1 therapy	18 Years - 75 Years	BioNTech SE
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	NCT04940299	Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Malignant Solid... Metastatic Blad... Metastatic Blad... Metastatic Lung... Metastatic Mela... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Uret... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Lung ... Stage IVB Lung ... Unresectable Me...	Ipilimumab Nivolumab Tocilizumab	18 Years -	M.D. Anderson Cancer Center
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma	NCT04695977	Melanoma Advanced Melano... Metastatic Mela... Unresectable Me...	CMP-001 Nivolumab	18 Years -	Regeneron Pharmaceuticals
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	NCT02224781	Clinical Stage ... Clinical Stage ... Metastatic Mela... Recurrent Melan... Unresectable Me...	Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Echocardiograph... Ipilimumab Multigated Acqu... Nivolumab Quality-of-Life... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI	NCT01266603	Melanoma	HDIL-2 recMAGE-A3 + AS...	18 Years -	M.D. Anderson Cancer Center
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy	NCT03719131	Cutaneous Melan... Cutaneous Melan... Stage III Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... Unresectable Me...	Nivolumab Rituximab and H... Ipilimumab	18 Years -	Emory University
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	NCT05896839	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Carc... Metastatic Mela... Metastatic Merk... Metastatic Skin... Unresectable Ba... Unresectable Me... Unresectable Me... Unresectable Sk...	Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Kidney Biopsy Magnetic Resona... Nivolumab Prednisone Sirolimus	18 Years -	National Cancer Institute (NCI)
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations	NCT05103891	Melanoma BRAF V600 Mutat... Unresectable Me... Metastatic Mela...	Binimetinib Ora...	18 Years - 65 Years	Pierre Fabre Medicament
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	NCT02721459	Melanoma Skin Cancer	XL888 Vemurafenib Cobimetinib	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	NCT05896839	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Carc... Metastatic Mela... Metastatic Merk... Metastatic Skin... Unresectable Ba... Unresectable Me... Unresectable Me... Unresectable Sk...	Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Kidney Biopsy Magnetic Resona... Nivolumab Prednisone Sirolimus	18 Years -	National Cancer Institute (NCI)
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients	NCT01638676	Melanoma	Vemurafenib Metformin	18 Years -	University of Louisville
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Ipilimumab and Imatinib Mesylate in Advanced Cancer	NCT01738139	Advanced Malign... C-KIT Tyrosine ... Clinical Stage ... Metastatic Gast... Metastatic Mali... Metastatic Mela... Pathologic Stag... Unresectable Me... Unresectable So...	Imatinib Mesyla... Ipilimumab	15 Years -	M.D. Anderson Cancer Center
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma	NCT06377111	Melanoma (Skin)	C-PAN Nivolumab Ipilimumab	18 Years -	University Health Network, Toronto
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	NCT02595866	AIDS-Related No... Clinical Stage ... Clinical Stage ... Hepatocellular ... HIV Infection Kaposi Sarcoma Locally Advance... Locally Advance... Metastatic Lung... Metastatic Mali... Metastatic Mela... Non-Hodgkin Lym... Recurrent Class... Recurrent Malig... Refractory Clas... Refractory Mali... Stage III Lung ... Stage IV Lung C... Unresectable Me...	Antiretroviral ... Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	NCT01726738	Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel...	BRAF inhibitor ...	18 Years -	UNC Lineberger Comprehensive Cancer Center
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma	NCT02302339	Melanoma	glembatumumab v... glembatumumab v... glembatumumab v... glembatumumab v...	18 Years -	Celldex Therapeutics
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations	NCT05810740	Melanoma BRAF V600 Mutat... Unresectable Me... Metastatic Mela...	Binimetinib Ora...	18 Years - 65 Years	Pierre Fabre Medicament
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors	NCT04616248	Anatomic Stage ... Metastatic Brea... Prognostic Stag... Unresectable Br... Metastatic Mela... Unresectable Me... Cutaneous Squam... Merkel Cell Car... Soft Tissue Sar... Bone Sarcoma Sarcoma,Soft Ti... Sarcoma of Bone	Anti-CD40 Agoni... Poly ICLC Radiation Thera... Recombinant Flt...	18 Years -	University of Southern California
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	NCT04527549	Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me...	Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime...	18 Years -	Eastern Cooperative Oncology Group
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma	NCT01107665	Stage III Melan... Stage IV Melano... Unresectable Me...	Pazopanib and P...	18 Years -	University of California, Irvine
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma	NCT06377111	Melanoma (Skin)	C-PAN Nivolumab Ipilimumab	18 Years -	University Health Network, Toronto
Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study	NCT04645680	Clinical Stage ... Clinical Stage ... Metastatic Mela... Pathologic Stag... Pathologic Stag... Unresectable Me...	Dietary Interve... Dietary Interve... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Sargramostim (GM-CSF) + PD-1	NCT04703426	Unresectable Me... Metastatic Mela... Stage III Melan... Stage IV Melano...	Sargramostim (G... Pembrolizumab (...	18 Years -	Dana-Farber Cancer Institute
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	NCT02721459	Melanoma Skin Cancer	XL888 Vemurafenib Cobimetinib	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma	NCT04526899	Melanoma Stage ... Melanoma Stage ... Unresectable Me...	BNT111 Cemiplimab	18 Years -	BioNTech SE
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma	NCT05303493	NSCLC Stage IV Melanoma Stage ... Unresectable Me... Advanced Non-Sm...	Camu Camu Capsu...	18 Years -	Centre hospitalier de l'Université de Montréal (CHUM)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT01134614	Advanced Melano... Metastatic Mela... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ipilimumab Sargramostim	18 Years -	National Cancer Institute (NCI)
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung	NCT05717140	Clinical Stage ... Metastatic Mali... Metastatic Mela... Recurrent Melan... Unresectable Me...	Aerosol Sargram... Biospecimen Col... Computed Tomogr... Magnetic Resona... Medical Device ... Nivolumab	18 Years -	Mayo Clinic
Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma	NCT05398640	Unresectable Me... Metastatic Mela...	Lifileucel	18 Years -	Iovance Biotherapeutics, Inc.
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	NCT01726738	Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel...	BRAF inhibitor ...	18 Years -	UNC Lineberger Comprehensive Cancer Center
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	NCT04521075	Melanoma Stage ... Unresectable Me... NSCLC Stage IV	Fecal Microbial...	18 Years -	Ella Therapeutics Ltd
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations	NCT05810740	Melanoma BRAF V600 Mutat... Unresectable Me... Metastatic Mela...	Binimetinib Ora...	18 Years - 65 Years	Pierre Fabre Medicament
Ipilimumab and Imatinib Mesylate in Advanced Cancer	NCT01738139	Advanced Malign... C-KIT Tyrosine ... Clinical Stage ... Metastatic Gast... Metastatic Mali... Metastatic Mela... Pathologic Stag... Unresectable Me... Unresectable So...	Imatinib Mesyla... Ipilimumab	15 Years -	M.D. Anderson Cancer Center
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma	NCT04337931	Unresectable Me... Metastatic Mela... Cancer Cancer of Skin Melanoma Melanoma (Skin)	sotigalimab	18 Years -	Apexigen America, Inc.
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma	NCT02115243	Unresectable Me...	Ipilimumab	18 Years - 99 Years	Duke University
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	NCT01726738	Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel...	BRAF inhibitor ...	18 Years -	UNC Lineberger Comprehensive Cancer Center
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers	NCT03816332	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Mela... Metastatic Merk... Metastatic Skin... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ba... Unresectable Me... Unresectable Me...	Ipilimumab Nivolumab Prednisone Tacrolimus	18 Years -	National Cancer Institute (NCI)
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	NCT02965716	Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Pembrolizumab Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	NCT05628883	Metastatic Mela... Unresectable Me... Acral Melanoma Mucosal Melanom... Cutaneous Melan... Ocular Melanoma Uveal Melanoma Iris Melanoma Conjunctival Me... Non-Cutaneous M...	TBio-4101 Cyclophosphamid... Fludarabine Interleukin-2	18 Years - 75 Years	H. Lee Moffitt Cancer Center and Research Institute
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)	NCT03679767	Metastatic Non-... Locally Advance... Metastatic Urot... Unresectable Me... Metastatic Mela... Locally Advance... Metastatic Clea...	Retifanlimab	18 Years -	Incyte Corporation
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT01134614	Advanced Melano... Metastatic Mela... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ipilimumab Sargramostim	18 Years -	National Cancer Institute (NCI)
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group
Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma	NCT05398640	Unresectable Me... Metastatic Mela...	Lifileucel	18 Years -	Iovance Biotherapeutics, Inc.
Post-ATU Study of Nivolumab	NCT03325257	Melanoma	Routine care	18 Years -	Nantes University Hospital
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT01950390	Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Bevacizumab Ipilimumab	18 Years -	National Cancer Institute (NCI)
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	NCT05896839	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Carc... Metastatic Mela... Metastatic Merk... Metastatic Skin... Unresectable Ba... Unresectable Me... Unresectable Me... Unresectable Sk...	Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Kidney Biopsy Magnetic Resona... Nivolumab Prednisone Sirolimus	18 Years -	National Cancer Institute (NCI)
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma	NCT02115243	Unresectable Me...	Ipilimumab	18 Years - 99 Years	Duke University
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	NCT02020707	Cervical Adenoc... Cervical Adenos... Cervical Adenos... Cervical Carcin... Cervical Squamo... Clinical Stage ... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Und... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Femal... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Perit... Malignant Solid... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian High Gr... Ovarian Mucinou... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Unresectable Me... Uterine Corpus ...	Bevacizumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Mayo Clinic
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: